A new wave of “bench-to-bedside-to-bench” studies is cresting in the age of molecular medicine. Now basic research flows from the lab to clinic, and clinical research cycles back to generate laboratory breakthroughs. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG) exemplifies this cutting-edge advance. HPCGG pioneers have broken through the mysteries of hypertrophic cardiomyopathy, a disease of the heart that is the number one cause of sudden death in athletes. Utilizing the HPCGG’s novel infrastructure and approach, these cardiomyopathy researchers are pioneering a new era in personalized medicine.